Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116813 · ClinicalTrials.gov registry record · Phase 2
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
A Phase 2 study, sponsored by Addex Pharma S.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT05116813 is a Phase 2 study that was terminated before completion, run by Addex Pharma S.A.. The registered enrollment target is 17 participants.
The verdict
NCT05116813, a Phase 2 study, was terminated before completion, sponsored by Addex Pharma S.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.
Interventions
- DRUG Dipraglurant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05116813
The ClinicalTrials.gov registry entry for NCT05116813 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Addex Pharma S.A., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dipraglurant is the first listed.
NCT05116813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05116813 about?
NCT05116813 is a clinical study titled "Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy". This open-label study is designed to assess the long-term safety and tolerability of dipraglurant in PD patients for up to 52 weeks (at doses of 150-300 mg per day) for patients that have completed an Addex sponsored double-blind clinical trial of dipraglurant.
What is the current status of trial NCT05116813?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2021-10-25. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT05116813?
The interventions under investigation include: Dipraglurant (DRUG).
Who is sponsoring clinical trial NCT05116813?
This trial is sponsored by Addex Pharma S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.